Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
NCT ID: NCT06692894
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2024-11-05
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke.
* Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients.
* By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* This study will follow patients with MDS over 6 months.
* Participants will come to the hospital for the first visit. Participants will learn about the study, sign papers to join the study, and share some basic health information. Participants will also give a blood sample of 10 milliliters after not eating overnight.
* After the first visit, participants will come back to the hospital once a week for 3 weeks to give more blood samples after fasting overnight.
* The study team will call participants the day before each scheduled blood draw to remind you of your appointment.
* Then participants will return to the hospital for another visits once a month for the next 5 months. Participants will talk about any changes in their health and give a blood sample at each visit.
* Participants won't get any treatment as part of this study, but their participation will help researchers learn how inflammation affects the health of people with MDS
* Researchers will collect a small amount of blood (6-10 mL) per visit
* These blood collections are a normal part of medical care and won't require participants to come in more often than usual. The frequency of visits will be part of the routine care for myelodysplastic syndrome at the cancer center. Extra blood will be collected during standard of care blood draws in the clinic.
* Sessions will take about 20 minutes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults with Myelodysplastic syndromes
All participants will be in one group. Participants will by adults with Myelodysplastic syndromes. Blood will be taken at regular appointments that are part of standard care.
Observational
Blood will be collected from one cohort to identify potential blood biomarkers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational
Blood will be collected from one cohort to identify potential blood biomarkers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
* Eastern Cooperative Oncology Group (ECOG) performance status ≤3
* Expected survival of at least 6 months
* Ability to provide consent
Exclusion Criteria
* Hematopoietic stem cell transplantation expected within 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vermont
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diego Adrianzen Herrera
Medical Oncologist, Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vermont
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Diego Adrianzen Herrera, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00003256/UVMCC2406
Identifier Type: -
Identifier Source: org_study_id